# Onconetix, Inc.: overview ONCO · Nasdaq · CIK 1782107 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/onco.md) · [Financials](/companies/onco/financials.md) · [Filings](/companies/onco/filings.md) · [Insiders](/companies/onco/insiders.md) Latest reported revenue: [$17.1k](/filings/0001213900-26-089093.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-089093). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [407](/filings/0001213900-24-107088.md) | [712 d](/filings/0001213900-26-027725.md) | [102](/filings/0001213900-26-055483.md) | [106](/filings/0001213900-26-089093.md) | [304](/filings/0001213900-25-110142.md) | [304 d](/filings/0001213900-26-027725.md) | [21.5](/filings/0001213900-26-055483.md) | [17.1](/filings/0001213900-26-089093.md) | | Gross margin | % | [25.9%](/filings/0001213900-25-110142.md) | [92.7% d](/filings/0001213900-26-027725.md) | [45.1%](/filings/0001213900-26-055483.md) | [66.2%](/filings/0001213900-26-089093.md) | [88.6%](/filings/0001213900-25-110142.md) | [81.6% d](/filings/0001213900-26-027725.md) | [(7.7%)](/filings/0001213900-26-055483.md) | [25.1%](/filings/0001213900-26-089093.md) | | Operating margin | % | [(650.3%)](/filings/0001213900-25-110142.md) | [(4093.7%) d](/filings/0001213900-26-027725.md) | [(12369.2%)](/filings/0001213900-26-055483.md) | [(1817.4%)](/filings/0001213900-26-089093.md) | [(681.5%)](/filings/0001213900-25-110142.md) | [(422.1%) d](/filings/0001213900-26-027725.md) | [(47657.2%)](/filings/0001213900-26-055483.md) | [(15950.9%)](/filings/0001213900-26-089093.md) | | Net margin | % | [(940.7%)](/filings/0001213900-25-110142.md) | [(4134.7%) d](/filings/0001213900-26-027725.md) | [(8408.8%)](/filings/0001213900-26-055483.md) | [(2227.8%)](/filings/0001213900-26-089093.md) | [(2892.7%)](/filings/0001213900-25-110142.md) | [1867.5% d](/filings/0001213900-26-027725.md) | [(19643.4%)](/filings/0001213900-26-089093.md) | [(16748.3%)](/filings/0001213900-26-089093.md) | | Diluted EPS | $ per share | [(249.08)](/filings/0001213900-25-110142.md) | not reported | [(227.25)](/filings/0001213900-26-055483.md) | [(237.91)](/filings/0001213900-26-089093.md) | [(6.25)](/filings/0001213900-25-110142.md) | not reported | [(6.71)](/filings/0001213900-26-055483.md) | [(1.28)](/filings/0001213900-26-089093.md) | | Free cash flow | $k | [(1,149) d](/filings/0001213900-25-110142.md) | [(922) d](/filings/0001213900-26-027725.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.1](/filings/0001213900-25-049687.md) | [2.5](/filings/0001213900-26-027725.md) | [0.8](/filings/0001213900-26-027725.md) | | Gross margin | % | not reported | not reported | [(1927.9%)](/filings/0001213900-25-049687.md) | [41.8%](/filings/0001213900-26-027725.md) | [77.6%](/filings/0001213900-26-027725.md) | | Operating margin | % | not reported | not reported | [(61634.5%)](/filings/0001213900-25-049687.md) | [(2238.0%)](/filings/0001213900-26-027725.md) | [(2190.0%)](/filings/0001213900-26-027725.md) | | Net margin | % | not reported | not reported | [(63986.5%)](/filings/0001213900-25-049687.md) | [(2325.2%)](/filings/0001213900-26-027725.md) | [(1721.0%)](/filings/0001213900-26-027725.md) | | Diluted EPS | $ per share | [(1.26)](/filings/0001213900-23-018635.md) | [(1.10)](/filings/0001213900-24-032225.md) | [(87.45)](/filings/0001213900-25-049687.md) | [(1823.39)](/filings/0001213900-26-027725.md) | [(16.56)](/filings/0001213900-26-027725.md) | | Free cash flow | $m | [(2.0)](/filings/0001213900-23-018635.md) | [(8.7)](/filings/0001213900-24-032225.md) | [(13.6)](/filings/0001213900-25-049687.md) | [(10.5)](/filings/0001213900-26-027725.md) | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/onco/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $15.3k | 13,548 | | New +13,548 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $285 | 252 | | New +252 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $164 | 145 | | New +145 | | [HOLLENCREST CAPITAL MANAGEMENT](/funds/1161722.md) | 2026-06-30 | $113 | 100 | | New +100 | | [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $58 | 51,398 | | New +51,398 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $24 | 21 | | New +21 | ## Recent filings [All 392 filings](/companies/onco/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 17:04 ET | [8-K](/filings/0001213900-26-112527.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-112527 | | 2026-10-23 | 11:40 ET | [8-K](/filings/0001213900-26-111944.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-111944 | | 2026-10-07 | 11:29 ET | [DEF 14A](/filings/0001213900-26-107480.md) | Proxy statement, period 2026-11-10 | 0001213900-26-107480 | | 2026-09-14 | 10:39 ET | [8-K](/filings/0001213900-26-099524.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-099524 | | 2026-08-31 | 16:05 ET | [S-1/A](/filings/0001213900-26-095703.md) | Registration statement, amended | 0001213900-26-095703 | | 2026-08-13 | 16:06 ET | [10-Q](/filings/0001213900-26-089093.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089093 | | 2026-08-12 | 13:52 ET | [S-1](/filings/0001213900-26-087986.md) | Registration statement | 0001213900-26-087986 | | 2026-07-29 | 17:02 ET | [8-K](/filings/0001213900-26-082879.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-082879 | | 2026-06-09 | 17:44 ET | [S-1](/filings/0001213900-26-066400.md) | Registration statement | 0001213900-26-066400 | | 2026-05-19 | 16:05 ET | [8-K](/filings/0001213900-26-058997.md) | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-058997 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-027725.md), filed Mar 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1e8c114c-d38d-4ebf-a56c-ace3e648f2fe) ## About the filer - CIK: 1782107 - Tickers: ONCO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 08:32 ET. No prices; not investment advice.